Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Merlin L Robb

Showing results (311-320 of 358) with videos related to

Pageof 36
Sort By:
Journal of Virology|May 15, 2015
Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine ResearchLindsay Wieczorek, Shelly J Krebs, Vaniambadi Kalyanaraman, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Long-Read Deep Sequencing Reveals High Rates of Multilineage Transmission and Rapid Viral Population Changes in Acute HIV InfectionJames I Mullins, Wenjie Deng, Elena E Giorgi, et al.
NPJ Vaccines|April 18, 2026
Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccineHolly Janes, Youyi Fong, Ying Huang, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Single-cell analyses reveal that monocyte gene expression profiles influence HIV-1 reservoir size in acutely treated cohortsPhilip K Ehrenberg, Aviva Geretz, Meta Volcic, et al.
Nature Communications|May 29, 2025
Single-cell analyses identify monocyte gene expression profiles that influence HIV-1 reservoir size in acutely treated cohortsPhilip K Ehrenberg, Aviva Geretz, Meta Volcic, et al.
The Journal of Infectious Diseases|May 29, 2012
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trialsDavid C Montefiori, Chitraporn Karnasuta, Ying Huang, et al.
The Journal of Clinical Investigation|March 18, 2020
Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral reboundEvan M Cale, Hongjun Bai, Meera Bose, et al.
The Journal of Clinical Investigation|February 14, 2023
Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adultsKristen W Cohen, Andrew Fiore-Gartland, Stephen R Walsh, et al.
The Lancet. Microbe|May 18, 2024
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trialBrittany L Ober Shepherd, Paul T Scott, Jack N Hutter, et al.
Medrxiv : the Preprint Server for Health Sciences|December 16, 2022
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein VaccineGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
Pageof 36

Showing results (311-320 of 358) with videos related to

Sort By:
Pageof 36
Journal of Virology|May 15, 2015
Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine ResearchLindsay Wieczorek, Shelly J Krebs, Vaniambadi Kalyanaraman, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Long-Read Deep Sequencing Reveals High Rates of Multilineage Transmission and Rapid Viral Population Changes in Acute HIV InfectionJames I Mullins, Wenjie Deng, Elena E Giorgi, et al.
NPJ Vaccines|April 18, 2026
Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccineHolly Janes, Youyi Fong, Ying Huang, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Single-cell analyses reveal that monocyte gene expression profiles influence HIV-1 reservoir size in acutely treated cohortsPhilip K Ehrenberg, Aviva Geretz, Meta Volcic, et al.
Nature Communications|May 29, 2025
Single-cell analyses identify monocyte gene expression profiles that influence HIV-1 reservoir size in acutely treated cohortsPhilip K Ehrenberg, Aviva Geretz, Meta Volcic, et al.
The Journal of Infectious Diseases|May 29, 2012
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trialsDavid C Montefiori, Chitraporn Karnasuta, Ying Huang, et al.
The Journal of Clinical Investigation|March 18, 2020
Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral reboundEvan M Cale, Hongjun Bai, Meera Bose, et al.
The Journal of Clinical Investigation|February 14, 2023
Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adultsKristen W Cohen, Andrew Fiore-Gartland, Stephen R Walsh, et al.
The Lancet. Microbe|May 18, 2024
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trialBrittany L Ober Shepherd, Paul T Scott, Jack N Hutter, et al.
Medrxiv : the Preprint Server for Health Sciences|December 16, 2022
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein VaccineGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
Pageof 36